Biomarker-guided acute kidney injury risk assessment under liberal versus restrictive fluid therapy - the prospective-randomized MAYDAY-trial

Sci Rep. 2024 Jul 24;14(1):17094. doi: 10.1038/s41598-024-68079-2.

Abstract

Acute kidney injury (AKI) prevalence in surgical patients is high, emphasizing the need for preventative measures. This study addresses the insufficient evidence on nephroprotective intraoperative fluid resuscitation and highlights the drawbacks of relying solely on serum creatinine/urine output to monitor kidney function. This study assessed the impact of intraoperative fluid management on AKI in female breast cancer patients undergoing autologous breast reconstruction, utilizing novel urinary biomarkers (TIMP-2 and IGFBP-7). In a monocentric prospective randomized controlled trial involving 40 patients, liberal (LFA) and restrictive (FRV) fluid management strategies were compared. TIMP-2 and IGFBP-7 biomarker levels were assessed using the NephroCheck (bioMerieux, France) test kit at preoperative, immediate postoperative, and 24-h postoperative stages. FRV showed significantly higher immediate postoperative biomarker levels, indicating renal tubular stress. FRV patients had 21% (4/19) experiencing AKI compared to 13% (2/15) in the LFA group according to KDIGO criteria (p = 0.385). Restrictive fluid resuscitation increases the risk of AKI in surgical patients significantly, emphasizing the necessity for individualized hemodynamic management. The findings underscore the importance of urinary biomarkers in early AKI detection.

Keywords: Acute kidney injury; Breast neoplasms/surgery; Breast reconstruction; Fluid therapy; Intraoperative fluid management; Urinary biomarkers.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Acute Kidney Injury* / diagnosis
  • Acute Kidney Injury* / etiology
  • Acute Kidney Injury* / therapy
  • Acute Kidney Injury* / urine
  • Adult
  • Aged
  • Biomarkers* / urine
  • Breast Neoplasms / surgery
  • Female
  • Fluid Therapy* / methods
  • Humans
  • Insulin-Like Growth Factor Binding Proteins* / blood
  • Insulin-Like Growth Factor Binding Proteins* / urine
  • Middle Aged
  • Prospective Studies
  • Risk Assessment
  • Tissue Inhibitor of Metalloproteinase-2* / urine

Substances

  • Biomarkers
  • insulin-like growth factor binding protein-related protein 1
  • Insulin-Like Growth Factor Binding Proteins
  • Tissue Inhibitor of Metalloproteinase-2
  • TIMP2 protein, human